Colin Bristow
Stock Analyst at UBS
(1.59)
# 3,478
Out of 5,124 analysts
105
Total ratings
40.32%
Success rate
-6.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $9.03 | +10.74% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $453.36 | +20.43% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $122.74 | -8.75% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $75.96 | +5.32% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.51 | +42.45% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.13 | -11.50% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $25.42 | -33.12% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $327.31 | -2.54% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.11 | +89.57% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $24.90 | +12.45% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $105.26 | +14.00% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $175.99 | +14.78% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.60 | +900.00% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $771.87 | +42.38% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $21.52 | +676.02% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,074.68 | -60.92% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $17.18 | -88.36% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.24 | +703.57% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $228.49 | -36.10% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $53.94 | +39.04% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.91 | +1,261.26% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.65 | +59.29% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $9.03
Upside: +10.74%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $453.36
Upside: +20.43%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $122.74
Upside: -8.75%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $75.96
Upside: +5.32%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.51
Upside: +42.45%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.13
Upside: -11.50%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $25.42
Upside: -33.12%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $327.31
Upside: -2.54%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.11
Upside: +89.57%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $24.90
Upside: +12.45%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $105.26
Upside: +14.00%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $175.99
Upside: +14.78%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.60
Upside: +900.00%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $771.87
Upside: +42.38%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $21.52
Upside: +676.02%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,074.68
Upside: -60.92%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $17.18
Upside: -88.36%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.24
Upside: +703.57%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $228.49
Upside: -36.10%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $53.94
Upside: +39.04%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.91
Upside: +1,261.26%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.65
Upside: +59.29%